Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.
Copyright © 2015 by the American Osteopathic Association.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Taieb V, et al. Value Health Nov;18(7):A598.
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Diabetic Dyslipidemia in Practice
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
An Update on Oral Prostanoids: Advancing Care for PAH?
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
New Patient-Friendly Options for Managing Insulin Dosing
Glaucoma Progression.
Updates on CVOT Data and Clinical Comparisons That Matter
SGLT2 Inhibitors and Their Clinical Impact:
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
What Comes Second?.
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence.
Updates on Outcomes for Novel T2D Therapies
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Clinical Application of New CV Outcomes Data
GLP-1 Receptor Agonists: How Early Is Appropriate?
A Deep Dive Into CVOTs.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Case Study Role of DPP-4 Inhibitors
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Early and Intensive T2D Management:
Breaking Down the CVOTs
Insulin/GLP-1 Agonist Combinations
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic Therapy
Navigating Treatment Options in PAH
CV Outcomes and Adherence With GLP-1 RAs
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Oral Combination Therapy for T2D
Patient-Centered Management in BRAF-Positive Metastatic Melanoma
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Improving Overall Health
Getting PPG Under Control
2015 EASD In Review: CV Risk management in t2dm
Emerging Combination Injectable Therapy A New Era in Diabetes Care
ADA/EASD general recommendations for type 2 diabetes management (1).
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Multilevel Intervention Most scientific proof about developing health and health patronage.
Fixed-Ratio Combination Therapy in T2DM
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Antihyperglycemic therapy in adults with type 2 diabetes
In the Know.
Presentation transcript:

Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin

Program Goals

Options for Prandial Control

Pramlintide

Incretin Agents

Algorithm for Adding/Intensifying Prandial Control

When Is It Time to Add Basal Insulin?

Adding Prandial Insulin

Scientific Rationale for Combining Basal Insulin With a GLP-1 Receptor Agonist

Adding Lixisenatide* to Basal Insulin

Fixed-Dose Combinations of GLP-1 Receptor Agonists Plus Basal Insulin Studied in T2D Patients

Discussing Prandial Therapy Options With the Patient

CVD Outcome Trials

DPP-4 Inhibitors

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)